glimepiride has been researched along with Innate Inflammatory Response in 15 studies
glimepiride: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)." | 9.34 | Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020) |
| " This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin." | 9.15 | The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. ( Forst, T; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Musholt, PB; Pfützner, A; Schöndorf, T, 2011) |
| "The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin." | 9.15 | Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. ( Bonaventura, A; Bossi, AC; Derosa, G; Fogari, E; Franzetti, IG; Guazzini, B; Maffioli, P; Putignano, P; Querci, F; Testori, G, 2011) |
| "The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging." | 9.15 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011) |
| "Nonalcoholic fatty liver disease (NAFLD) is a liver phenotype of type 2 diabetes and obesity." | 7.11 | Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. ( Arai, K; Goto, H; Harada, K; Honda, M; Iida, N; Kaneko, S; Kita, Y; Mizukoshi, E; Nakamura, H; Nakano, Y; Takamura, T; Takata, N; Takeshita, Y; Tanaka, T; Tsujiguchi, H; Yamashita, T, 2022) |
| " This study aimed to evaluate the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin on the biomarkers of inflammation, thrombosis, and atherosclerosis in T2DM patients with symptomatic coronary artery disease (CAD)." | 5.34 | Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease. ( Kabel, M; Mostafa, T; Omran, G; Shokry, A; Werida, R, 2020) |
| " This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin." | 5.15 | The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. ( Forst, T; Fuchs, W; Hohberg, C; Lehmann, U; Löbig, M; Müller, J; Musholt, PB; Pfützner, A; Schöndorf, T, 2011) |
| "The aim of this study was to evaluate the effect of exenatide compared to glimepiride on body weight, glycemic control and insulin resistance in type 2 diabetic patients taking metformin." | 5.15 | Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. ( Bonaventura, A; Bossi, AC; Derosa, G; Fogari, E; Franzetti, IG; Guazzini, B; Maffioli, P; Putignano, P; Querci, F; Testori, G, 2011) |
| "The aim of this study was to compare the effect of pioglitazone, an insulin sensitizer, with glimepiride, an insulin secretagogue, on atherosclerotic plaque inflammation by using serial (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging." | 5.15 | Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. ( Harada, H; Hayabuchi, N; Ikeda, H; Imaizumi, T; Ishibashi, M; Kaida, H; Kodama, N; Mawatari, K; Mizoguchi, M; Nitta, Y; Oba, T; Tahara, A; Tahara, N; Yamagishi, S; Yasukawa, H, 2011) |
| "The aim of the study was to compare the effects of vildagliptin added to pioglitazone or glimepiride on metabolic and insulin resistance related-indices in poorly controlled type 2 diabetic patients (T2DM)." | 5.14 | Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. ( Ciccarelli, L; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Mereu, R; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA, 2010) |
| "Nonalcoholic fatty liver disease (NAFLD) is a liver phenotype of type 2 diabetes and obesity." | 3.11 | Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. ( Arai, K; Goto, H; Harada, K; Honda, M; Iida, N; Kaneko, S; Kita, Y; Mizukoshi, E; Nakamura, H; Nakano, Y; Takamura, T; Takata, N; Takeshita, Y; Tanaka, T; Tsujiguchi, H; Yamashita, T, 2022) |
| "15 obese patients with type 2 diabetes were studied, all using metformin (1-2 g/day) and sulfonylurea (glimiperide)." | 1.51 | Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. ( Digtiar, NI; Kaidashev, IP; Kaidasheva, EI; Savchenko, LG; Selikhova, LG; Shlykova, OA; Vesnina, LE, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 13 (86.67) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Takeshita, Y | 1 |
| Honda, M | 1 |
| Harada, K | 1 |
| Kita, Y | 1 |
| Takata, N | 1 |
| Tsujiguchi, H | 1 |
| Tanaka, T | 1 |
| Goto, H | 1 |
| Nakano, Y | 1 |
| Iida, N | 1 |
| Arai, K | 1 |
| Yamashita, T | 1 |
| Mizukoshi, E | 1 |
| Nakamura, H | 1 |
| Kaneko, S | 1 |
| Takamura, T | 1 |
| Werida, R | 1 |
| Kabel, M | 1 |
| Omran, G | 1 |
| Shokry, A | 1 |
| Mostafa, T | 1 |
| Garvey, WT | 1 |
| Van Gaal, L | 1 |
| Leiter, LA | 1 |
| Vijapurkar, U | 1 |
| List, J | 1 |
| Cuddihy, R | 1 |
| Ren, J | 1 |
| Davies, MJ | 1 |
| Soustek, MS | 1 |
| Balsa, E | 1 |
| Barrow, JJ | 1 |
| Jedrychowski, M | 1 |
| Vogel, R | 1 |
| Gygi, SP | 1 |
| Puigserver, P | 1 |
| Ishola, IO | 1 |
| Akataobi, OE | 1 |
| Alade, AA | 1 |
| Adeyemi, OO | 1 |
| Savchenko, LG | 1 |
| Digtiar, NI | 1 |
| Selikhova, LG | 1 |
| Kaidasheva, EI | 1 |
| Shlykova, OA | 1 |
| Vesnina, LE | 1 |
| Kaidashev, IP | 1 |
| Heyer, EJ | 1 |
| Mergeche, JL | 1 |
| Bruce, SS | 1 |
| Connolly, ES | 1 |
| El-Haggar, SM | 1 |
| Farrag, WF | 1 |
| Kotkata, FA | 1 |
| Derosa, G | 2 |
| Maffioli, P | 2 |
| Ferrari, I | 1 |
| Mereu, R | 1 |
| Ragonesi, PD | 1 |
| Querci, F | 2 |
| Franzetti, IG | 2 |
| Gadaleta, G | 1 |
| Ciccarelli, L | 1 |
| Piccinni, MN | 1 |
| D'Angelo, A | 1 |
| Salvadeo, SA | 1 |
| Schöndorf, T | 1 |
| Musholt, PB | 1 |
| Hohberg, C | 1 |
| Forst, T | 1 |
| Lehmann, U | 1 |
| Fuchs, W | 1 |
| Löbig, M | 1 |
| Müller, J | 1 |
| Pfützner, A | 1 |
| Putignano, P | 1 |
| Bossi, AC | 1 |
| Bonaventura, A | 1 |
| Guazzini, B | 1 |
| Testori, G | 1 |
| Fogari, E | 1 |
| Tawakol, A | 1 |
| Finn, AV | 1 |
| Mizoguchi, M | 1 |
| Tahara, N | 1 |
| Tahara, A | 1 |
| Nitta, Y | 1 |
| Kodama, N | 1 |
| Oba, T | 1 |
| Mawatari, K | 1 |
| Yasukawa, H | 1 |
| Kaida, H | 1 |
| Ishibashi, M | 1 |
| Hayabuchi, N | 1 |
| Harada, H | 1 |
| Ikeda, H | 1 |
| Yamagishi, S | 1 |
| Imaizumi, T | 1 |
| Marwick, TH | 1 |
| Narula, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver[NCT02649465] | Phase 4 | 40 participants (Actual) | Interventional | 2015-11-11 | Completed | ||
| The Effect of Adding Vildagliptin Versus Glimepiride to Metformin on Markers of Inflammation, Thrombosis, and Atherosclerosis in Diabetic Patients With Symptomatic Coronary Artery Diseases[NCT03693560] | Phase 4 | 80 participants (Actual) | Interventional | 2018-10-08 | Completed | ||
| A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Co[NCT00968812] | Phase 3 | 1,452 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Effect of Augmentation of Cerebral Blood Flow on Neuropsychometric Performance After Carotid Endarterectomy in Type II Diabetic Patients[NCT00597545] | 10 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Half of DM patients had EEG changes and therefore were excluded.) | |||
| Neurologic and Neuropsychometric Outcome in Patients Undergoing Carotid Endarterectomy[NCT00597883] | 585 participants (Actual) | Observational | 2003-03-31 | Completed | |||
| Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213] | Phase 4 | 60 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Detection of Plaque Inflammation and Visualization of Anti-Inflammatory Effects of Pioglitazone on Plaque Inflammation in Subjects With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus by FDG-PET/CT[NCT00722631] | 70 participants (Actual) | Interventional | 2007-05-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 104 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change. (NCT00968812)
Timeframe: Baseline, Week 104
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -0.65 |
| Canagliflozin 300 mg | -0.74 |
| Glimepiride | -0.55 |
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -0.82 |
| Canagliflozin 300 mg | -0.93 |
| Glimepiride | -0.81 |
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean percent change. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percent change (Least Squares Mean) |
|---|---|
| Canagliflozin 100 mg | -4.2 |
| Canagliflozin 300 mg | -4.7 |
| Glimepiride | 1.0 |
The table below shows the percentage of patients who experienced at least 1 documented hypoglycemic event from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in percentages. (NCT00968812)
Timeframe: Day 1 (Baseline) and Week 52
| Intervention | Percentage of patients (Number) |
|---|---|
| Canagliflozin 100 mg | 5.6 |
| Canagliflozin 300 mg | 4.9 |
| Glimepiride | 34.2 |
Battery of neuropsychometric tests to evaluate a variety of cognitive functions. (NCT00597545)
Timeframe: Post-operatively at 1 day
| Intervention | participants (Number) |
|---|---|
| Conventional Shunt | 1 |
| Prophylactic Shunt | 2 |
8 trials available for glimepiride and Innate Inflammatory Response
| Article | Year |
|---|---|
Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial.
Topics: Benzhydryl Compounds; Diabetes Mellitus, Type 2; Fibrosis; Glucosides; Humans; Inflammation; Liver; | 2022 |
Comparative clinical study evaluating the effect of adding Vildagliptin versus Glimepiride to ongoing Metformin therapy on diabetic patients with symptomatic coronary artery disease.
Topics: Adiponectin; Atherosclerosis; Biomarkers; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus, | 2020 |
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
Topics: Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Canagliflozin; Diabetes Mellitus, | 2018 |
Effect of ketotifen in obese patients with type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Huma | 2015 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Topics: Adamantane; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fema | 2010 |
The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study.
Topics: Aged; Biomarkers; Blood Coagulation; Blood Platelets; Body Mass Index; Diabetes Mellitus, Type 2; Fe | 2011 |
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Femal | 2011 |
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Topics: Aged; Anti-Inflammatory Agents; Aortic Diseases; Aortography; Biomarkers; Blood Glucose; C-Reactive | 2011 |
7 other studies available for glimepiride and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Inhibition of the ER stress IRE1α inflammatory pathway protects against cell death in mitochondrial complex I mutant cells.
Topics: Apoptosis; Cytoprotection; Electron Transport Complex I; Endoplasmic Reticulum Stress; Endoribonucle | 2018 |
Glimepiride prevents paraquat-induced Parkinsonism in mice: involvement of oxidative stress and neuroinflammation.
Topics: Animals; Antioxidants; Cytokines; Dose-Response Relationship, Drug; Inflammation; Lipid Peroxidation | 2019 |
Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes.
Topics: Actins; Ceruloplasmin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gene Expression | 2019 |
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hy | 2013 |
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hy | 2013 |
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hy | 2013 |
Inflammation and cognitive dysfunction in type 2 diabetic carotid endarterectomy patients.
Topics: Aged; Cognition Disorders; Diabetes Mellitus, Type 2; Endarterectomy, Carotid; Glyburide; Humans; Hy | 2013 |
Imaging inflammatory changes in atherosclerosis multimodal imaging hitting stride.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Aortic Diseases; Aortography; Atherosclerosis; Carotid Art | 2011 |
Imaging of pharmacologic intervention decoding therapeutic mechanism or defining effectiveness?
Topics: Anti-Inflammatory Agents; Aortic Diseases; Aortography; Carotid Artery Diseases; Diabetes Mellitus, | 2011 |